Selenium in the treatment of mild-to-moderate Graves' orbitopathy: a 5-year prospective controlled cohort study.

Purpose: Graves' orbitopathy (GO) is the main extrathyroidal manifestation of Graves' disease. However, limited studies have investigated the actual efficacy of selenium in GO therapy. This longitudinal study explored the effect of selenium on QOL and prognosis of patients with mild-to-moderate GO.

Serum Trace Elements Profile in Graves' Disease Patients with or without Orbitopathy in Northeast China.

Objective: The purpose of the present study was to investigate serum trace elements in Graves' disease (GD) patients with or without orbitopathy in Northeast China.

Methods: Patients with newly diagnosed Graves' disease (HyGD) ( = 66), GD patients with euthyroid status or subclinical thyroidism after treatment (EUGD) ( = 55), GO patients with euthyroid status or subclinical thyroidism after treatment (GO) ( = 57), and normal controls (NC) ( = 66) were enrolled in this study. Serum trace elements were measured with ICP-MS.